Why did Amphastar Pharmaceuticals (AMPH) stock move recently?

On 9/2/2026, Amphastar Pharmaceuticals moved +3.4% — No specific company catalyst or filing identified for the 3.4% gain; recent news includes a small institutional investment and upcoming conference presentation, while earnings and guidance from early August showed a modest beat but no major outlook change. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Amphastar Pharmaceuticals (AMPH) overvalued or fairly valued?

MarketChacha shows Amphastar Pharmaceuticals's valuation in context — a trailing P/E of about 13.0, a forward P/E of about 7.2, a price-to-book of about 1.3 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Amphastar Pharmaceuticals's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.40×) from reported figures — education, not a rating.

What is Amphastar Pharmaceuticals's revenue?

Amphastar Pharmaceuticals reported revenue of $719.9M for FY2025, with net profit of $98.1M, per official filings.

What is the share price of Amphastar Pharmaceuticals (AMPH)?

Amphastar Pharmaceuticals last traded at $23.74 (+3.4% on the day), as of 9/2/2026 — a delayed quote shown for education, not investment advice.

Amphastar Pharmaceuticals

AMPH · NYSE · Healthcare · United States

Snapshot

TickerAMPH

ExchangeNYSE

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

CountryUnited States

Employees1,976

HeadquartersRancho Cucamonga, United States

Websitewww.amphastar.com

Filings tracked20

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Who owns it

Insiders30.8%
Institutions69.2%
Public & other0.0%

306 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.12.28%
Dimensional Fund Advisors LP5.42%
State Street Corporation3.86%
Vanguard Capital Management LLC3.48%
American Century Companies Inc2.77%
Marshall Wace LLP2.51%
Geode Capital Management, LLC2.28%
Fuller & Thaler Asset Management Inc.2.23%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Margin has compressed by about 7.7 points over the period — profitability is trending down.

Cash conversion1.40×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend21.3% → 13.6%

Margin has compressed by about 7.7 points over the period — profitability is trending down.

Growth qualityrev 6% · PAT -16%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $194.8M · EPS 0.69

Est. earnings growth +9.4%

Next fiscal year

Rev $784.4M · EPS 2.64

Est. earnings growth +7.1%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$719.9M

Net margin

13.6%

ROE

12.4%

Revenue CAGR (2y)

+5.7%

Profit CAGR (2y)

-15.6%

EPS (FY2025)

2.03

Net profit (FY2025)

$98.1M

Ask MarketChacha about AMPH

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Sep 2, 2026
No specific company catalyst or filing identified for the 3.4% gain; recent news includes a small institutional investment and upcoming conference presentation, while earnings and guidance from early August showed a modest beat but no major outlook change.
source 1 ↗source 2 ↗· confidence: low
Jul 28, 2026
No clear company-specific catalyst identified in recent filings or credible news coverage; the stock moved with the broader market or sector.
· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$719.9M	$98.1M	2.03	13.6%	12.4%
FY2024	$732.0M	$159.5M	3.06	21.8%	21.8%
FY2023	$644.4M	$137.5M	2.60	21.3%	21.5%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$183.9M	$30.3M	0.67	16.5%
2026Q1	$171.2M	$6.4M	0.14	3.8%
2025Q3	$191.8M	$17.4M	0.37	9.0%
2025Q2	$174.4M	$31.0M	0.64	17.8%
2025Q1	$170.5M	$25.3M	0.51	14.8%
2024Q3	$191.2M	$40.4M	0.78	21.1%
2024Q2	$182.4M	$37.9M	0.73	20.8%
2024Q1	$171.8M	$43.2M	0.81	25.1%
2023Q3	$180.6M	$49.2M	0.91	27.3%
2023Q2	$145.7M	$26.1M	0.49	17.9%
2023Q1	$140.0M	$26.0M	0.50	18.6%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Results of operations, Exhibits
SEC8/6/2026material
10-Q filing
SEC8/6/2026
8-K — Executive/director change
SEC7/13/2026material
8-K — Other events
SEC7/8/2026material
8-K — Shareholder vote results
SEC6/3/2026material
8-K — Results of operations, Exhibits
SEC5/7/2026material
10-Q filing
SEC5/7/2026
8-K — Other events
SEC3/16/2026material
8-K — Material agreement, Exhibits
SEC3/6/2026material
8-K — Executive/director change, Exhibits
SEC3/6/2026material
8-K — Results of operations, Exhibits
SEC2/26/2026material
10-K filing
SEC2/26/2026
8-K — Material agreement, Reg FD disclosure, Exhibits
SEC1/12/2026material

2025

8-K — Results of operations, Exhibits
SEC11/6/2025material
10-Q filing
SEC11/6/2025
8-K — Material agreement
SEC10/24/2025material
8-K — Material agreement
SEC9/18/2025material
8-K — Material agreement, Reg FD disclosure, Exhibits
SEC8/12/2025material
8-K — Results of operations, Exhibits
SEC8/7/2025material
10-Q filing
SEC8/7/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.